Vorinostat (VOR) and capecitabine (CAP) in recurrent and/or metastatic squamous cell carcinoma of head and neck (RMHNSCC): A study of the Princess Margaret Phase II Consortium.

e17001 Background: VOR is a small molecule inhibitor of histone deacetylase (HDAC). Preclinical studies demonstrate that HDAC inhibition is synergistic or additive with other anti-cancer treatments...